止痛散离子导入法合羟考酮控释片治疗中重度癌痛临床研究

目的 观察止痛散离子导入法合羟考酮控释片治疗中重度癌痛的临床疗效。方法 〖JP2〗将中重度癌性疼痛患者56例随机分为治疗组和对照组，每组28例，对照组给予羟考酮控释片口服，治疗组在对照组疗法基础上联合止痛散离子导入，两组均以10 d为1个疗程，连续治疗3个疗程，观察并比较两组镇痛疗效、平均镇痛持续时间、羟考酮控释片最终滴定剂量、卡氏功能状态评分（Karnorfsky'' s performance scale, KPS）及不良反应。结果 治疗组镇痛疗效显著优于对照组 (P<0.05)， 在提高平均镇痛持续时间及KPS评分方面均显著优于对照组(P<0.01)，羟考酮控释片最终滴定剂量和不良反应显著低于对照组 (P<0.05)。结论 止痛散离子导入法合羟考酮控释片治疗中重度癌痛安全有效。

Clinical Efficacy of Pain-Relieving Powder Iontophoresis Combined with Controlled-Release Oxycontin Tablets in Treatment of Moderate or Severe Cancer Pain

Objective To observe the clinical efficacy of pain-relieving powder iontophoresis combined with controlled-release oxycontin tablets in the treatment of moderate or severe cancer pain. Methods Fifty-six patients with moderate or severe cancer pain were randomly and equally divided into treatment group and control group. The control group was orally given controlled-release oxycontin tablets, while the treatment group received pain-relieving powder iontophoresis in addition to controlled-release oxycontin tablets. Both groups were treated for 3 courses (10 d per course). Analgesic effect, mean duration of analgesia, the final titrated dose of controlled-release oxycontin tablets, Karnofsky Performance Scale (KPS) score, and adverse events were evaluated and compared between the two groups. Results The treatment group had a significantly better analgesic effect than the control group (P<0.05). The treatment group was significantly superior to the control group in terms of mean duration of analgesia and KPS score (P<0.01). Moreover, the final titrated dose of controlled-release oxycontin tablets and incidence of adverse events were significantly lower in the treatment group than in the control group (P<0.05). Conclusion Pain-relieving powder iontophoresis combined with controlled-release oxycontin tablets is safe and effective in the treatment of moderate or severe cancer pain.